Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.
IVBM All Coverage
All series
All IVBM All Coverage
Advertisement
The dilemma of Alzheimer disease in primary care, as well as other health challenges in aging populations, was the focus of a recent Institute for Value-Based Medicine® event in Portland, Oregon.
Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.
Coverage from the Institute for Value-Based Medicine® event with Oncology Consultants of Houston, held in Texas on October 11, 2022.
Coverage from the Institute for Value-Based Medicine® event in Denver, Colorado, held October 5, 2022. The event was held in partnership with Rocky Mountain Cancer Centers.
Lucy Langer, MD, MSHS, national medical director, oncology and genomics, MSHS, national medical director, oncology and genomics, UnitedHealthcare, discussed value-based contracting at the IVBM® session October 5, 2022.
Coverage from the Institute for Value-Based Medicine® event in Nashville, Tennessee, held November 17, 2022. The event was held in partnership with Vanderbilt-Ingram Cancer Center.
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
During an Institute for Value-Based Medicine® event held in New York City, Samyukta Mullangi, MD, MBA, fellow in medical oncology at Memorial Sloan Kettering Cancer Center, discussed how disruptions from the COVID-19 pandemic are ushering in health care delivery reform.
Advertisement
Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
Coverage from the New York City presentation of the Institute for Value-Based Medicine, co-chaired by Emeline Aviki, MD, MBA, of Memorial Sloan Kettering Cancer Center (MSKCC), and Robert Daly, MD, MBA, medical oncologist and lung cancer specialist at MSKCC.
A featured presentation at the Irvine, California, meeting of the Institute for Value-Based Medicine discussed how a patient with long-term HIV was cured through a transplant.
Coverage from the Irvine, California, meeting of the Institute for Value-Based Medicine, chaired by Joseph Alvarnas, MD, vice president for government affairs at City of Hope and chief clinical advisor, AccessHope.
Coverage from the Minnesota meeting of the Institute for Value-Based Medicine, chaired by Rajini Katipamula-Malisetti, MD, vice president of medical oncology at Minnesota Oncology.
Coverage from the Atlanta meeting of the Institute for Value-Based Medicine, chaired by Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services, Emory Healthcare and Emory Winship Cancer Institute.
The Enhancing Oncology Model (EOM) will be the successor to the Oncology Care Model.
Co-hosted by Memorial Sloan Kettering Cancer Center, the most recent Institute for Value-Based Medicine® event took place on September 22, with a focus on improving cancer care delivery through innovation.
On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
The Institute for Value-Based Medicine series visits Texas Oncology in Austin.
Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Why "tech-enabled" solutions make sense and how the Music City became the a health care hub.
Oncologist and health tech veteran Bobby Green, MD, who practiced for 17 years in Florida and was previously with Flatiron, is now Thyme Care’s president and chief medical officer. He has relocated to Nashville, Tennessee, to launch Thyme Care.
The Institute of Value-Based Medicine® (IVBM), hosted by Tennessee Oncology, brought health care leaders together on April 21 in Nashville, Tennessee, to discuss oncology care delivery—and to see colleagues in person, some for the first time since 2020.
After the Oncology Care Model (OCM) expires at the end of June, Tennessee Oncology will take what it learned from the model and apply it to commercial value-based care arrangements and potentially the next Medicare model, said Leah Owens, DNP, RN, executive director of care transformation at Tennessee Oncology.
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology.
